Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody ... to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or ...

The Food and Drug Administration on Monday approved Merck's shot designed to protect ... in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control ...